These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 17696882

  • 1. A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells.
    Croucher DR, Saunders DN, Stillfried GE, Ranson M.
    Biochem J; 2007 Dec 01; 408(2):203-10. PubMed ID: 17696882
    [Abstract] [Full Text] [Related]

  • 2. Signalling networks associated with urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in breast cancer tissues: new insights from protein microarray analysis.
    Wolff C, Malinowsky K, Berg D, Schragner K, Schuster T, Walch A, Bronger H, Höfler H, Becker KF.
    J Pathol; 2011 Jan 01; 223(1):54-63. PubMed ID: 21125664
    [Abstract] [Full Text] [Related]

  • 3. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S, Larsen JV, Pedersen KE, Petersen HH, Egelund R, Christensen A, Jensen JK, Gliemann J, Andreasen PA.
    FEBS J; 2006 Nov 01; 273(22):5143-59. PubMed ID: 17042782
    [Abstract] [Full Text] [Related]

  • 4. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan 01; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 5. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth.
    Webb DJ, Thomas KS, Gonias SL.
    J Cell Biol; 2001 Feb 19; 152(4):741-52. PubMed ID: 11266465
    [Abstract] [Full Text] [Related]

  • 6. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
    Duffy MJ, Duggan C.
    Clin Biochem; 2004 Jul 19; 37(7):541-8. PubMed ID: 15234235
    [Abstract] [Full Text] [Related]

  • 7. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL.
    J Pathol; 2001 Sep 19; 195(2):236-43. PubMed ID: 11592104
    [Abstract] [Full Text] [Related]

  • 8. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
    Cancer Res; 2000 Feb 01; 60(3):636-43. PubMed ID: 10676647
    [Abstract] [Full Text] [Related]

  • 9. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N, Maguire TM, Riisbro R, Geurts-Moespot A, O'Donovan N, Schmitt M, McGreal G, McDermott E, O'Higgins N, Brünner N, Sweep CG, Duffy MJ.
    Oncol Rep; 2005 Jul 01; 14(1):235-9. PubMed ID: 15944795
    [Abstract] [Full Text] [Related]

  • 10. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
    Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brünner N, Harbeck N, Klijn JG, Foekens JA.
    Cancer Res; 2004 Jul 01; 64(13):4563-8. PubMed ID: 15231667
    [Abstract] [Full Text] [Related]

  • 11. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations.
    Chazaud B, Ricoux R, Christov C, Plonquet A, Gherardi RK, Barlovatz-Meimon G.
    Am J Pathol; 2002 Jan 01; 160(1):237-46. PubMed ID: 11786417
    [Abstract] [Full Text] [Related]

  • 12. Urokinase-type plasminogen activator system and breast cancer (Review).
    Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K.
    Oncol Rep; 2005 Jul 01; 14(1):105-12. PubMed ID: 15944776
    [Abstract] [Full Text] [Related]

  • 13. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K, Brünner N.
    Clin Cancer Res; 1997 Feb 01; 3(2):233-9. PubMed ID: 9815678
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW, Kjoller L, Petersen HH, Andreasen PA.
    Biochem J; 1998 Jan 01; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [Abstract] [Full Text] [Related]

  • 16. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S, Vrhovec I, Svetic B, Cufer T.
    Clin Breast Cancer; 2002 Jun 01; 3(2):138-46. PubMed ID: 12123538
    [Abstract] [Full Text] [Related]

  • 17. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H.
    J Urol; 2005 Aug 01; 174(2):461-5. PubMed ID: 16006865
    [Abstract] [Full Text] [Related]

  • 18. Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.
    Al-Ejeh F, Croucher D, Ranson M.
    Exp Cell Res; 2004 Jul 01; 297(1):259-71. PubMed ID: 15194441
    [Abstract] [Full Text] [Related]

  • 19. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
    Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H.
    Cancer Res; 1994 May 15; 54(10):2527-30. PubMed ID: 8168072
    [Abstract] [Full Text] [Related]

  • 20. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
    Allan EH, Martin TJ.
    J Cell Physiol; 1995 Dec 15; 165(3):521-9. PubMed ID: 7593231
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.